Evidence map›Paper›PMID 30522903›Full record

ArticleUrologic oncology2019

Analyzing the current practice patterns and views among urologists regarding focal therapy for prostate cancer.

Amit L Jain, Abhinav Sidana, Mahir Maruf, Dordaneh Sugano, Brian Calio, Bradford J Wood, Peter A Pinto

Open access · greenAbstract read
In one paragraph

Article in Urologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Shifting tides: A survey analysis of urologists' evolving attitudes toward focal therapy for prostate cancer.Indian journal of urology : IJU : journal of the Urological Society of India
    Article
  8. Article
  9. Focal therapy for prostate cancer - index lesion treatment vs. hemiablation. A matter of definition.International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Amit L JainUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: jain.amitlodha@gmail.com.
Abhinav SidanaUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Mahir MarufUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Dordaneh SuganoUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Brian CalioUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Bradford J WoodCenter for Interventional Oncology, National Cancer Institute & Clinical Center, National Institutes of Health, Bethesda, MD.
Peter A PintoUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
National Institutes of Health · USNational Cancer Institute · US

Funding

Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Prostate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2M
Intramural NIH HHS ZIA BC011081Intramural NIH HHS ZID BC011242
6 · The paper itself

Abstract

INTRODUCTION AND

objectiveFocal therapy (FT) for localized prostate cancer (CaP) has been shown to have encouraging short-term oncological outcomes, excellent preservation of functional outcomes and is increasing in popularity in urologic community. We aim to evaluate the preferences and practice trends among urologists regarding this treatment strategy.

methodsA 20 item online questionnaire was designed to collect information on urologists' views and use of FT. The survey was sent to the members of the Endourological Society and the American Urological Association. Multivariate logistic regression analysis was done to determine predictors for utilization of FT.

resultsA total of 425 responses were received [American Urological Association: 319, Endourological Society: 106]. Mean age of respondents was 53(SD: 11.3) years. Although half of the respondents (50.8%) believed FT to be moderate to extremely beneficial in the treatment of CaP, only 24.2% (103) of the respondents currently utilize FT in their practice. Respondents who were fellowship trained in urologic oncology were more likely to consider FT to be at least moderately beneficial (P < 0.001). Surgeon's experience (greater than 15 years in urology practice) (P = 0.025) and seeing more than 10 patients with new CaP diagnosis per month (P = 0.002) were independent predictors of FT utilization for localized CaP. While the most common setting for utilization of FT was in patients with unilateral intermediate-risk (72.8%) CaP, a small percentage of respondents also used FT for patients with unilateral high-risk CaP and bilateral intermediate risk (21.4% and 10.7%, respectively). Most common reasons for not using FT were the lack of belief in 'index lesion theory' (63.2%), lack of experience (41.3%), lack of belief in FT's efficacy (41.1%), lack of infrastructure (35.8%), difficult salvage treatment in cases of recurrence (22.7%) and high cost (21.8%). About 57.6% would use FT more often in an office or outpatient setting if they had access to reliable and cost-effective options.

conclusionsOnly a quarter of our respondents utilize FT in their practice with surgeon's experience being the important independent predictor for using FT. Majority of respondents though consider FT to be beneficial in CaP management, would use it more often if provided more reliable and cost-effective options. Over time, experience and accessibility to reliable methods to perform FT may lead to further utilization of this novel treatment strategy.

Indexed as

Ablation TechniquesAdultHumansMaleMiddle AgedOrgan Sparing TreatmentsPatient SelectionPractice Patterns, Physicians'ProstateProstatic NeoplasmsSurveys and QuestionnairesTreatment OutcomeUnited StatesUrologistsUrologyFocal therapyMultiparametric MRIProstate cancerSurvey

Identifiers

PMID30522903
PMCPMC8258689
OpenAlexW2903535843

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.